Skip to main content

Table 2 Characteristics of patients with rheumatoid arthritis and of controls

From: Expression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritis

Characteristic RA patients Controlsa
  Total (n = 89) Erosive RA (n = 46) Nonerosive RA (n = 43) Serum (n = 62) Synovial fluid (n = 21)
Age, years 58 ± 2 62 ± 1.8 54 ± 3.1** 52 ± 1.4 64 ± 2
Gender, F/M 60/29 29/17 31/12 46/16 12/9
Erosivity 46/89 46 0   
No. (%) RF+ 51 41 (89%) 10 (23%)***   
Disease duration, years 11 ± 1.3 13 ± 1.3 8.2 ± 1.3*   
No. (%) with disease duration <3 years 27 (30%) 9 (20%) 18 (42%)   
CRP, mg/l 40 ± 8 42 ± 7 36 ± 7   
WBC count Blood Synovial fluid 7.7 ± 2.2
13 ± 3.5
8.0 ± 0.4
14.3 ± 3.4
7.1 ± 0.4
12.6 ± 2.3
  
Synovial fluid 13 ± 3.5 14.3 ± 3.4 12.6 ± 2.3   
No. (%) DMARD-treated 47 (53%) 36 (76%) 11 (26%)   
   Methotrexate 31 25 6***   
   Other 16 11 5   
  1. Values are means ± standard errors of the mean unless otherwise indicated.
  2. aControls were healthy subjects or patients with degenerative or traumatic joint disease. *P = 0.0047; **P = 0.0014; ***P > 0.0001. CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; F, female; M, male; RF, rheumatoid factor; WBC, white blood cell.